[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Amylyx Pharmaceuticals Inc (AMLX)

Amylyx Pharmaceuticals Inc (AMLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,870,835
  • Shares Outstanding, K 111,423
  • Annual Sales, $ 0 K
  • Annual Income, $ -144,740 K
  • EBIT $ -162 M
  • EBITDA $ -167 M
  • 60-Month Beta -0.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 17.27

Options Overview Details

View History
  • Implied Volatility 60.96% (+3.72%)
  • Historical Volatility 154.08%
  • IV Percentile 7%
  • IV Rank 15.68%
  • IV High 275.22% on 08/03/26
  • IV Low 21.11% on 08/26/26
  • Expected Move (DTE 20) 3.91 (11.26%)
  • Put/Call Vol Ratio 1.05
  • Today's Volume 1,383
  • Volume Avg (30-Day) 4,575
  • Put/Call OI Ratio 1.12
  • Today's Open Interest 61,779
  • Open Int (30-Day) 53,630
  • Expected Range 30.83 to 38.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.38
  • Number of Estimates 4
  • High Estimate $-0.35
  • Low Estimate $-0.40
  • Prior Year $-0.37
  • Growth Rate Est. (year over year) -2.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.05 +82.41%
on 07/29/26
41.14 -15.56%
on 08/21/26
+15.19 (+77.70%)
since 07/28/26
3-Month
12.62 +175.28%
on 06/08/26
41.14 -15.56%
on 08/21/26
+20.52 (+144.30%)
since 05/28/26
52-Week
9.15 +279.88%
on 09/02/25
41.14 -15.56%
on 08/21/26
+25.32 (+268.79%)
since 08/28/25

Most Recent Stories

More News
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public...

AMLX : 34.74 (-6.56%)
Stocks Finish Lower as Chipmakers and AI Stocks Fall

The S&P 500 Index ($SPX ) (SPY ) closed down by -0.69% on Tuesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.22%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -1.68%....

TRGP : 287.82 (-0.39%)
AMAT : 461.67 (-4.29%)
AVGO : 368.79 (-0.74%)
SNDK : 1,484.98 (unch)
INTU : 358.06 (+2.89%)
ADI : 361.78 (-3.40%)
FN : 414.36 (-4.24%)
TRI : 106.22 (+1.38%)
TXN : 258.64 (-2.96%)
$IUXX : 29,433.43 (-0.70%)
BBWI : 19.22 (+3.06%)
DUOL : 146.98 (+2.88%)
AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial

Amylyx shares rally on promising avexitide, a GLP-1 receptor antagonist, data. But should you load up on AMLX stock on strength today? Let’s find out!

AMLX : 34.74 (-6.56%)
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock. In...

AMLX : 34.74 (-6.56%)
Chipmaker Sell-Off Weighs on Stock Indices

The S&P 500 Index ($SPX ) (SPY ) is down by -0.61% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -1.76%. E-mini S&P futures...

TRGP : 287.82 (-0.39%)
AMAT : 461.67 (-4.29%)
SNDK : 1,484.98 (unch)
INTU : 358.06 (+2.89%)
ADI : 361.78 (-3.40%)
FN : 414.36 (-4.24%)
TRI : 106.22 (+1.38%)
TXN : 258.64 (-2.96%)
$IUXX : 29,433.43 (-0.70%)
BBWI : 19.22 (+3.06%)
DUOL : 146.98 (+2.88%)
ASML : 1,696.16 (-2.24%)
Stocks Retreat as Global Bond Yields Rise

The S&P 500 Index ($SPX ) (SPY ) is down by -0.42% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -1.17%. E-mini S&P futures...

ALK : 42.32 (+0.28%)
SNDK : 1,484.98 (unch)
TRI : 106.22 (+1.38%)
BBWI : 19.22 (+3.06%)
DUOL : 146.98 (+2.88%)
STX : 829.76 (-2.06%)
WDC : 459.45 (-0.55%)
AMD : 465.58 (-2.33%)
SPY : 769.35 (-0.23%)
ADSK : 260.66 (-3.67%)
AMLX : 34.74 (-6.56%)
MU : 932.86 (-0.27%)
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

LUCIDITY met FDA-agreed-upon primary endpoint; avexitide demonstrated a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo (p=0.000003) ...

AMLX : 34.74 (-6.56%)
Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia...

AMLX : 34.74 (-6.56%)
Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results

Last participant completed final study visit in the 16-week double-blind period of the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia; topline data on track and anticipated...

AMLX : 34.74 (-6.56%)
Can Amylyx Still Call This a Pipeline Story After Thursday?

Barchart Research What to Expect from AMLX Earnings AMLX Generated August 5, 2026 Current Price $21.85 EPS Estimate $$-0.36 Consensus Rating Strong Buy Average Move 4.87% Can Amylyx Still Call This a Pipeline...

AMLX : 34.74 (-6.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Amylyx Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It focuses on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 39.99
2nd Resistance Point 38.84
1st Resistance Point 36.79
Last Price 34.74
1st Support Level 33.58
2nd Support Level 32.43
3rd Support Level 30.38

See More

52-Week High 41.14
Last Price 34.74
Fibonacci 61.8% 28.92
Fibonacci 50% 25.14
Fibonacci 38.2% 21.37
52-Week Low 9.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.